Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2021. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Lisa Miller - Director-Investor Relations Rick Hawkins - President, Chairman & Chief Executive Officer John McKew - Chief Operating Officer & Chief Scientific Officer Gene Kennedy - Chief Medical Officer Carl Langren - Chief Financial Officer Lori Lawley - Senior Vice President, Finance & Corporate Controller Conference Call Participants Charles Duncan - Cantor Fitzgerald Lina Kaminski - JonesTradin ...

= ulos PHARMA Corporate Presentation March 17, 2021 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "wil ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2020 Earnings Conference Call March 9, 2021 4:30 PM ET Company Participants Lisa Miller – Director-Investor Relations Rick Hawkins – Chief Executive Officer, President and Chairman John McKew – Chief Operating Officer and Chief Scientific Officer Gene Kennedy – Chief Medical Officer Carl Langren – Chief Financial Officer Conference Call Participants Charles Duncan – Cantor Fitzgerald Ed White – H.C. Wainwright Lina Kaminski – JonesTrading Yasmeen Rahimi – Piper Sandler El ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2020. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorpora ...

Corporate Presentation November 2020 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2020. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 Delaware 42-1491350 4200 Marathon Blvd #200 Austin, Texas 78756 (512) 215-2630 (Address, including zip code, ...

| --- | --- | |-------|-------| | | | | | | Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "cou ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q3 2020 Results Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Lisa Miller - Director, IR Rick Hawkins - CEO, President, and Chairman John McKew - COO and CSO Eugene Kennedy - CMO Carl Langren - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Ed White - H.C. Wainwright Elemer Piros - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Lumos Pharma Third Quarter Earnings Call. At this time, all pa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2020. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) (State or other jurisdiction of incorpor ...